News Listing

Exciting things are happening in 2026—introducing BIMZELX Navigate® program enhancements! As of January 1, 2026, the BIMZELX Navigate program has been upgraded with new features and streamlined processes to better support both your patients and practice.

Support is available to help your patients with lupus nephritis start and stay on a prescribed Genentech medication. Genentech is committed to helping patients access…

NORM proudly supports lupus patients and the Lupus Foundation, and we honor the rheumatologists who care for them every day. In May, communities across the country come together to recognize Lupus Awareness Month — a time dedicated to increasing understanding, supporting those living with lupus, and advocating for better care and research. On May 10, the global community also recognizes World ...

Permanent HCPCS Level II Coding for Organon’s biosimilars to PROLIA (denosumab) and XGEVA (denosumab) is now effective. Q-code: Q5162

We want to make you aware of a new CMS requirement that requires your urgent attention to avoid potential disruption to eligibility checks and benefit investigations performed on your behalf by Amgen.

The national conversation around Pharmacy Benefit Managers (PBMs) often centers on drug pricing. In rheumatology practices, however, the impact goes far beyond cost. It affects operations, financial stability, physician morale, and—most importantly—patient access to care.

Winter weather disruptions are becoming more frequent—and more unpredictable. For rheumatology practices, the impact goes far beyond delayed appointments. Weather-related closures can disrupt temperature-sensitive medications, staffing availability, patient prioritization, and drug deliveries, all while rescheduling becomes increasingly difficult.

SLEDAI-2K is a Global Disease Index used to assess disease activity in patients with SLE.¹ There is an extensive range of disease activity indices of systemic lupus erythematosus (SLE) based on clinical studies and trials. However, many are complex given the intent for which they were created. The SLEDAI-2K tool is often used in clinical trials to measure SLE disease activity…

Effective October 1, 2025, new ICD-10-CM codes will be available for use as released by the Centers for Medicare and Medicaid Services (CMS) regarding Rheumatoid Arthritis.

The Access and Reimbursement Resource Guide offers resources to assist with the acquisition of products, including SAPHNELO, and features the....